What Stimovar Treats: Main Uses and Benefits

Stimovar (Gonadotrophin, Serum) is a veterinary medicine that supports reproductive health in livestock. Its purpose is focused on playing a role in managing disruptions in the natural reproductive cycle and supports breeding programs. The active substance is used for helping address the symptom of ovarian acyclicity and supports the goal of enhanced reproductive outcomes in synchronised animals.

The medicine is used for managing reproductive challenges, including anoestrus (the absence of a heat cycle), delayed return to oestrus following weaning, suboptimal follicular development, and the necessity for group breeding synchronisation.

“In situations involving acyclicity, this medication may assist with achieving fertility status and contributes to managing the duration of unproductive periods.”

Clinical Focus: Reproductive Acyclicity

Therapeutic Benefit	Use Context
Assists with initiating heat cycles	Applied in animals exhibiting anoestrus or delayed cycling patterns.
Supporting synchronisation	Relevant for fixed-time Artificial Insemination and embryo transfer protocols.
Fertility assistance	May assist with achieving successful fertilization and conception by supporting the reproductive cycle.

Stimovar is officially designated in governmental regulatory documents as a veterinary medicinal product containing Equine Serum Gonadotrophin, intended only for use in animals such as Cattle, Sheep, Goats, Pigs, and Dogs. It is not approved for human therapeutic use by major regulatory agencies like the FDA or EMA.

---

Populations for Whom Use Is Prohibited or Restricted

Classification	Who Must Not Use/Handle the Product (Label-Based)
Absolute Exclusion (Therapeutic Use)	All human populations
Contraindicated (Target Animal)	Pregnant animals (the target species)
Mandatory Handling Restriction	Pregnant women, women intending to become pregnant, or those whose pregnancy status is unknown (due to the active ingredient's documented teratogenic effects in lab animals)
Condition-Specific Exclusion	Individuals with known hypersensitivity to gonadotropins or any excipients

---

Regulatory Summary

The eligibility profile is strictly defined by its veterinary status. Use is limited to the target animal species under veterinary prescription. The label imposes specific safety constraints on human handlers, mandating that pregnant women and those with known gonadotropin hypersensitivity must avoid contact to prevent accidental exposure, which is officially classified as a risk.

Interactions with other medicines and products

Official regulatory documentation for Stimovar (Gonadotrophin, Serum) defines its interaction profile based primarily on administration constraints and incompatibilities rather than classical pharmacokinetic drug-drug interactions.

Interaction Classifications

Classification	Official Regulatory Status / Description
Interaction severity classification	Classified by Pharmaceutical Incompatibility and Co-administration Timing Restriction.
Mechanistic basis of interactions	Classical pharmacokinetic (PK) and pharmacodynamic (PD) interactions are officially documented as Not known or None known.

---

Official Interaction Statements

Interaction Type	Regulatory Restriction
Pharmaceutical Incompatibility	The reconstituted product must not be mixed with any other veterinary medicinal product except the diluent supplied.
Timing-based Restriction (Anthelmintics)	Co-administration is not recommended at the time of injection.
Timing-based Restriction (Vaccines)	Co-administration is not recommended at the time of injection.

---

This interaction structure ensures adherence to procedural constraints during preparation and administration. No specific substances are officially documented as causing altered exposure (AUC/Cmax) of Gonadotrophin, Serum. Furthermore, no interactions with food, alcohol, or herbal products are explicitly documented in the official regulatory labeling.

Stimovar is a preparation containing Equine Serum Gonadotrophin (eSG), a glycoprotein hormone structurally and functionally analogous to Follicle-Stimulating Hormone (FSH) and, to a lesser extent, Luteinizing Hormone (LH). The active substance primarily targets the Follicle-Stimulating Hormone receptor (FSHR), a G-protein coupled receptor (GPCR) expressed on the surface of granulosa cells within the ovary.

Stimovar acts as a full agonist at the FSHR, initiating intracellular signaling via the adenylyl cyclase/cAMP/PKA pathway. Binding to FSHR activates the G s protein, which stimulates adenylyl cyclase to catalyze the conversion of ATP to cyclic AMP (cAMP). The resultant increase in intracellular cAMP concentration activates Protein Kinase A (PKA). PKA, in turn, phosphorylates various downstream transcription factors, notably the cAMP response element-binding protein (CREB).

This cascade culminates in the regulation of target gene expression, specifically promoting follicular development and steroidogenesis within the ovaries. System-level physiological consequences involve the direct stimulation of ovarian follicular growth and, dependent on the dose, an increase in the number of follicles proceeding to maturation and ovulation.

How to Use Stimovar: Administration Guidelines

Stimovar (Gonadotrophin, Serum) is a veterinary medicinal product used according to highly specified, protocol-based instructions. The general principle of its use is a single, timed administration as part of a structured breeding synchronization program.

Administration and Preparation

Instruction Type	Detail
Route of Administration	The medicine is delivered parenterally, primarily by Intramuscular (IM) injection or, alternatively, by Subcutaneous (SC) injection.
Preparation	The product is supplied as a lyophilized powder and solvent. These components must be reconstituted immediately prior to use by combining them and mixing until a homogenous solution is achieved.
Injection Site	When administered, the injection is directed into the anterior half of the neck area.

---

Dosing Patterns and Scheduling

The dosage is determined by the species and the specific purpose, and the final International Unit (IU) amount must be adjusted based on the individual animal's characteristics.

For instance, the typical dose range for bovine anoestrus is 500–1000 IU, whereas the range for super-ovulation in cattle is higher, at 1500–3000 IU. A key instruction dictates that the dose must be selected based on the animal's age, breed, and season, with non-cycling animals generally requiring amounts toward the higher end of the range. The product is administered as a one-time event precisely timed relative to the removal of other hormonal agents, such as a progestogen device, to ensure procedural compliance with the breeding protocol.

This single, short-term injection is a necessary component to regulate the timing of the reproductive cycle as required by established protocols.

Research evidence / Overview of Studies for Stimovar

Stimovar (Gonadotrophin, Serum) was evaluated in a research context focusing on its use in veterinary medicine for research exploring reproductive cycles, primarily in livestock. The evidence base consists mainly of Randomized Controlled Trials (RCTs) and Controlled Field Studies designed to track specific reproductive markers in controlled settings.

---

Evidence for Use in Oestrus Synchronisation

Research has explored the use of the active substance in protocols designed for oestrus synchronisation, which was studied for examining reproductive timing in groups of animals.

The study designs available are typically short-term RCTs and Controlled Field Studies that included populations of Adult Cattle (cows and heifers) and Adult Sheep (ewes). Research examined key functional outcomes such as the time until the start of the heat cycle (oestrus onset) and the percentage of animals where oestrous response was observed following treatment. Longer-term reproductive outcomes, including pregnancy rates, conception rates, and final calving or lambing rates, were also monitored during the study periods.

Studies reported measurements of a time-dependent follicular response, and findings described patterns observed in the timing of the heat cycle and subsequent pregnancy rates in the observed populations. Some trials described patterns related to the overall reproductive outcomes measured compared to control groups. However, reports indicated that findings were mixed across various studies, suggesting that the outcomes may be associated with the specific synchronisation program used and other factors.

---

Evidence for Use in Managing Anoestrus and Ovarian Acyclicity

The active substance was evaluated in research exploring the use for anoestrus (the absence of a heat cycle) and other conditions associated with acyclicity.

Controlled Field Studies and RCTs were conducted during periods of increased symptom activity to see if the treatment was associated with the initiation of the heat cycle. The populations studied were Cattle and Sheep confirmed to be non-cycling. Research examined temporary physiological imbalance by monitoring outcomes such as the measured return to cyclicity and the resultant follicular development (often using imaging techniques).

---

Evidence Quality, Uncertainty, and Research Gaps

Certainty remains low in several areas of the evidence base. Evidence quality varies across studies due to differences in study design, animal management, and concurrent use of other agents in synchronisation protocols. Findings were mixed regarding the consistency of results across all possible breeds and physiological conditions.

Key limitations identified in the evidence base include:

• The optimal dosage is uncertain and may differ based on the breed, environment, and physiological state of the animal.
• Long-term effects are not fully established regarding the impact of repeated use on the subsequent reproductive health of the animals.
• Data for certain groups remain insufficient, particularly concerning the effects of the treatment on the animal's immune response or sensitization over time.

Key Studies & References

1. Effect of the method of estrus synchronization and PMSG dosage on estrus and twinning in Ethiopian Menz sheep

Common questions about Stimovar (FAQ)

Q: How long does the effect of Stimovar last after taking a dose?

Official pharmacokinetic studies indicate that the active substance stays in the body for an extended period. The drug's terminal half-life, which measures how long it takes for the concentration to significantly drop, typically ranges from 34 to 150 hours depending on the species treated. This long duration is consistent with the molecule's chemical classification.

Q: Is Stimovar available in a generic formulation?

The active substance in Stimovar is Gonadotrophin, Serum, which is the non-proprietary name also known as Equine Chorionic Gonadotropin (eCG). Products containing this specific active ingredient are commercially available from various manufacturers within this class of veterinary medicines.

Q: What medical conditions are listed as contraindications for Stimovar use?

Regulatory information describes several contraindications that prevent the use of this drug. For target animals, this includes pregnant animals and any animal with a known hypersensitivity (a severe allergic reaction risk) to gonadotropins or any of the product’s inactive ingredients.

Q: What kind of specialist typically prescribes Stimovar?

Stimovar is officially categorized as a Prescription Only Medicine (POM), which restricts its use. The medicine is reserved for use under the prescription and supervision of a licensed veterinary practitioner (veterinarian) for application strictly within animal health protocols.

Q: How quickly does Stimovar usually start working?

Following the injection, the active substance is quickly absorbed into the body. Official studies show that the drug typically reaches its maximum concentration in the bloodstream within approximately 8 to 16 hours after administration, depending on the species treated.

Q: What should be done about an uncommon side effect while using Stimovar?

Although rare, official product information acknowledges the possibility of a severe allergic event, such as anaphylactic shock. Official product information suggests that in such rare events, appropriate emergency treatment is administered by a qualified professional to manage the reaction.

Q: Is Stimovar a controlled substance?

Official classifications designate Stimovar as a Prescription Only Medicine (POM). While it is subject to strict rules for prescribing, record-keeping, and storage as a veterinary product, the active substance is not typically classified as a federally controlled drug in regulatory listings.

Q: What is the difference between the brand name and generic Stimovar ingredients?

Both brand name and generic versions of this medicine contain the same active substance, Gonadotrophin, Serum, which provides the therapeutic effect. The main difference lies in the excipients, which are the inactive ingredients (like stabilizers or diluents) that can vary between different manufacturers' products.

Q: Are there any specific lifestyle factors mentioned in official documents that affect Stimovar?

Official guidelines describe that the dose is determined based on the animal’s breed and the season in which it is administered. These factors, alongside the animal's reproductive status, influence the required dose.

Q: How is Stimovar eliminated from the body?

The regulatory literature indicates that the active substance is eliminated slowly due to its complex molecular structure. It is suggested that the drug is metabolized and broken down through natural physiological processes, primarily occurring in the liver and kidney.

Q: What should a person do if they suspect an allergic reaction to Stimovar?

Official safety instructions state that handlers are expected to seek medical advice immediately and present the medical professional with the product leaflet or label in the event of accidental self-injection or an adverse reaction.

How to Store and Dispose of Stimovar

Stimovar Injection, which is supplied as a powder and solvent, requires specific storage conditions that depend on whether the product has been reconstituted.

---

Storage Requirements

Product State	Temperature	Environmental Protection
Unopened (Powder & Solvent)	Store below 25°C	Protected from light
Reconstituted Solution	Store under refrigeration (2°C to 8°C)	Protected from light

The reconstituted solution must be used within 28 days. The product must be kept out of the sight and reach of children.

---

Disposal

Unused Stimovar or waste materials must be disposed of according to local requirements. The medicine should not be discarded via wastewater or household waste.